ArticleMediators of inflammation2026
Bone Marrow-Derived Mesenchymal Stem Cells (BM-MSCs) and Small Intestinal Submucosa (SIS) Hydrogel Composite Can Meliorate TNBS-Induced Experimental Colitis Through Regulating Inhibiting Macrophage Polarization Toward the M1 Phenotype.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
An imbalance of macrophage polarization exerts influence over inflammatory bowel disease (IBD) pathogenesis. To investigate how macrophage polarization influences IBD, we engineered a composite system consisting of small intestinal submucosa (SIS) hydrogel combined with bone marrow-derived mesenchymal stem cells (BM-MSCs). The therapeutic potential of this construct was assessed by examining its regulatory effects on macrophage polarization both in a 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis mouse model and in RAW264.7 macrophages in vitro. Clone formation assay was executed to identify the influence of MSC-SIS-conditioned medium on the proliferation of RAW264.7. CD206 and CD86 were measured by flow cytometric. Quantitative real-time PCR (qRT-PCR) was conducted to evaluate cytokine gene expression. Experimental colitis was induced in mice using TNBS. Disease severity was assessed by calculating the clinical disease activity index (CDAI). Colonic tissues were subjected to histological and morphometric analyses, and serum levels of inflammatory cytokines were quantified using enzyme-linked immunosorbent assay (ELISA). Data indicated that the BM-MSCs and SIS hydrogel composite significantly promoted Raw264.7 proliferation. Compared with the lipopolysaccharide (LPS) + MSCs group, treatment with the combined MSCs and SIS hydrogel construct demonstrated a more pronounced inhibitory effect on M1 phenotype the autophagy of LPS-induced RAW264.7 in vitro; what is more, BM-MSCs and SIS hydrogel greatly inhibited cytokine mRNA levels in LPS-stimulated Raw264.7 cells compared with treatment with MSCs solely. In addition, the results implied that the mice in TNBS + MSC + SIS group had alleviated colitis compared with the TNBS + MSCs group, and the interleukin (IL)-1β and tumor necrosis factor-α (TNF-α) levels in the serum also decreased. In conclusion, these results indicate a better wound healing effect of SIS hydrogel on BM-MSCs through promoting cell regeneration and inhibiting macrophage polarization towards the M1 phenotype in a TNBS-induced experimental mouse model.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.